← Back to Screener
CRISPR Therapeutics AG (CRSP)
Price$57.69
Favorite Metrics
Price vs S&P 500 (26W)-22.41%
Price vs S&P 500 (4W)14.92%
Market Capitalization$5.56B
All Metrics
Book Value / Share (Quarterly)$20.04
P/TBV (Annual)1.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)43.01%
Cash Flow / Share (Quarterly)$-3.87
Price vs S&P 500 (YTD)6.08%
Net Profit Margin (TTM)-16569.77%
EPS (TTM)$-6.51
10-Day Avg Trading Volume1.57M
EPS Excl Extra (TTM)$-6.51
Revenue Growth (5Y)38.05%
EPS (Annual)$-6.47
ROI (Annual)-30.26%
Net Profit Margin (5Y Avg)-14346.95%
Cash / Share (Quarterly)$20.60
Revenue Growth QoQ (YoY)-97.58%
ROA (Last FY)-25.67%
Revenue Growth TTM (YoY)-90.59%
EBITD / Share (TTM)$-6.21
ROE (5Y Avg)-15.26%
Operating Margin (TTM)-18933.65%
Cash Flow / Share (Annual)$-3.87
P/B Ratio2.89x
P/B Ratio (Quarterly)2.60x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1485.16x
Net Interest Coverage (TTM)13.24x
ROA (TTM)-26.72%
EV / EBITDA (TTM)15.43x
EPS Incl Extra (Annual)$-6.47
Current Ratio (Annual)13.32x
Quick Ratio (Quarterly)13.28x
3-Month Avg Trading Volume1.81M
52-Week Price Return52.74%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$22.53
P/S Ratio (Annual)1584.18x
Asset Turnover (Annual)0.00x
52-Week High$78.48
Operating Margin (5Y Avg)-15260.63%
EPS Excl Extra (Annual)$-6.47
CapEx CAGR (5Y)7.09%
Tangible BV CAGR (5Y)15.52%
26-Week Price Return-15.52%
Quick Ratio (Annual)13.28x
13-Week Price Return6.42%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.32x
Enterprise Value$5,212.921
Revenue / Share Growth (5Y)29.76%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-2.31%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-16466.24%
Cash / Share (Annual)$20.60
3-Month Return Std Dev66.87%
Net Income / Employee (TTM)$-1
ROE (Last FY)-30.26%
Net Interest Coverage (Annual)-0.66x
EPS Basic Excl Extra (Annual)$-6.47
P/FCF (TTM)51.00x
Receivables Turnover (TTM)0.28x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-6.51
Receivables Turnover (Annual)0.28x
ROI (TTM)-31.53%
P/S Ratio (TTM)1584.18x
Pretax Margin (5Y Avg)-14329.12%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$22.53
Price vs S&P 500 (52W)18.11%
Year-to-Date Return10.01%
5-Day Price Return1.46%
EPS Normalized (Annual)$-6.47
ROA (5Y Avg)-12.83%
Net Profit Margin (Annual)-16569.77%
Month-to-Date Return21.27%
Cash Flow / Share (TTM)$-4.22
EBITD / Share (Annual)$-6.21
Operating Margin (Annual)-18933.65%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-15.26%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-6.51
P/TBV (Quarterly)1.74x
P/B Ratio (Annual)2.60x
Pretax Margin (TTM)-16466.24%
Book Value / Share (Annual)$20.04
Price vs S&P 500 (13W)4.04%
Beta1.86x
P/FCF (Annual)12.16x
Revenue / Share (TTM)$0.04
ROE (TTM)-31.53%
52-Week Low$33.03
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.83
3.86
3.86
3.86
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CRSPCRISPR Therapeutics AG | 1584.18x | -90.59% | — | — | $57.69 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
CRISPR Therapeutics is a gene editing company developing therapies based on CRISPR/Cas9 technology to treat genetically defined diseases. The company's first approved drug, Casgevy (co-developed with Vertex Pharmaceuticals), addresses sickle-cell disease and transfusion-dependent beta-thalassemia. CRISPR's pipeline includes gene editing programs in immuno-oncology, cardiovascular disease, and Type 1 diabetes.